Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers

Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Yu ZuoYu-Min Shen

Abstract

The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL)in individual patients without antiphospholipid syndrome (APS) clinical manifestation is challenging. Our aim is to identify additional risk factors or potential candidate "second hits" for APS clinical events in a large cohort of ethnically diverse aPL-positive patients. We included 219 consecutive aPL-positive patients who attended clinic at our institution. All patients had at least 1 persistent high titer (≥99 percentiles) aPL. Independent risk factors for thrombosis and pregnancy morbidities among patients with positive aPL were evaluated. When assessing risk factors associated with pregnancy morbidities, only female controls of reproductive age (age ≤45) were used. Pearson χ2 analysis and multivariable logistic regression were used to evaluate correlation between different risk factors and clinical manifestations. Of the 219 aPL-positive patients, 120 (54.8%) patients had criteria APS clinical manifestations and 99 patients did not. A total of 46.1% were Caucasian, 26.4% of African descent, 16.9% Hispanic, 1.8% Asian, and 8.7% were unspecified. Among traditional risk factors and signs of endothelial injury, only hypertension ...Continue Reading

References

Aug 11, 2000·JAMA : the Journal of the American Medical Association·E M AntmanE Braunwald
Jun 13, 2001·JAMA : the Journal of the American Medical Association·B F GageM J Radford
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·P G de GrootF R Rosendaal
Jan 24, 2008·Circulation·Ralph B D'AgostinoWilliam B Kannel
Nov 26, 2010·Obstetrics and Gynecology·Aline D do PradoBernardo L Horta
Feb 3, 2011·Annals of the Rheumatic Diseases·Amelia RuffattiUNKNOWN Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology
May 11, 2011·Nature Reviews. Rheumatology·Pier Luigi MeroniFrancesco Tedesco
May 29, 2012·Lupus·M L Bertolaccini
Jan 15, 2013·Rheumatology·Savino SciasciaMaria Laura Bertolaccini
Mar 15, 2013·The New England Journal of Medicine·Bill Giannakopoulos, Steven A Krilis
Dec 11, 2013·Thrombosis Research·Aleksandra Matyja-BednarczykJacek Musiał
Jun 23, 2015·Annals of Internal Medicine·Jill P BuyonJane E Salmon
Oct 25, 2016·Autoimmunity Reviews·V PengoA Banzato
Jun 10, 2017·Arthritis & Rheumatology·Medha BarbhaiyaKaren H Costenbader

❮ Previous
Next ❯

Citations

Sep 9, 2018·American Journal of Reproductive Immunology : AJRI·Daisy Leon-MartinezVikki M Abrahams
Jul 5, 2019·The Medical Journal of Australia·Veronica MezhovFlavia M Cicuttini
Jan 6, 2022·Current Rheumatology Reports·Eleni Xourgia, Maria G Tektonidou

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Software Mentioned

SAS

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.